Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:21:03 EDT Fri 17 Apr 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:INKT - MINK THERAPEUTICS INC - http://www.inktomi.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
INKT - Q0.214.02·14.300.114.1726+0.04260.332.442731214.22  14.2208  13.7776.00  6.3412:01:47Apr 0315 min RT 2¢

Recent Trades - Last 10 of 312
Time ETExPriceChangeVolume
12:01:47Q14.17260.0426200
11:58:24Q14.13 1
11:57:51Q14.210.081
11:56:04Q14.13 5
11:51:37Q14.150.0210
11:51:32Q14.1212-0.00881
11:46:26Q14.01-0.124
11:45:32Q14.01-0.1280
11:43:57Q14.01-0.121
11:43:23Q14.13 1

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-04-03 07:30U:INKTNews ReleaseMiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
2026-04-02 07:30U:INKTNews ReleaseMiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
2026-04-01 07:30U:INKTNews ReleaseMiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
2026-03-31 07:30U:INKTNews ReleaseMiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
2026-03-17 07:30U:INKTNews ReleaseMiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs
2026-03-10 05:30U:INKTNews ReleaseMiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers
2026-02-03 21:30U:INKTNews ReleaseMiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
2026-01-08 12:00U:INKTNews ReleaseMiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
2025-11-20 11:43U:INKTNews ReleaseMiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors
2025-11-14 07:30U:INKTNews ReleaseMiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation
2025-11-07 09:00U:INKTNews ReleaseMiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1-Refractory Solid Tumors at SITC 2025
2025-11-05 09:07U:INKTNews ReleaseMiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
2025-10-30 09:00U:INKTNews ReleaseMiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
2025-09-29 07:30U:INKTNews ReleaseMiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors
2025-09-25 07:30U:INKTNews ReleaseMiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA
2025-09-18 07:30U:INKTNews ReleaseMiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development
2025-08-14 07:30U:INKTNews ReleaseMiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
2025-07-31 08:30U:INKTNews ReleaseMiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
2025-07-15 08:22U:INKTNews ReleaseMiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy
2025-07-11 07:30U:INKTNews ReleaseMiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer